Latest news and press releases about Pluri Inc. (PLUR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology.
Price
| Price | $1.14 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | -0.55 |
| EV / EBITDA | -1.72 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 203.55% |
| Return on Invested Capital | -117.79% |
| Return on Assets | -100.41% |
| Gross Margin | 19.00% |
| Operating Margin | -2412.14% |
| Net Margin | -2424.75% |
Related companies: ANTX · BOLD · IBIO · INTS · ITRM · JSPR · NXTC
Explore sector: Healthcare · Biotechnology
More sections of PLUR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks